Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Belantamab mafodotin by GSK for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Multiple Myeloma (Kahler Disease). According to...
Belantamab mafodotin by GSK for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Belantamab mafodotin by GSK for Amyloidosis: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Amyloidosis. According to GlobalData, Phase II...
Belantamab mafodotin by GSK for Relapsed Multiple Myeloma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData,...
Belantamab mafodotin by GSK for Refractory Multiple Myeloma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...